Atara Biotherapeutics Inc. (ATRA) Upgraded to Hold by Zacks Investment Research
Atara Biotherapeutics Inc. (NASDAQ:ATRA) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued on Monday.
According to Zacks, “Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology. The company’s lead programs are focused on myostatin and activin, members of the TGF-beta family of proteins that have demonstrated the potential to have therapeutic benefit in a number of clinical indications. Its lead product candidate is PINTA 745, which is in a Phase II clinical trial for the treatment of protein-energy wasting in end-stage renal disease patients. Atara Biotherapeutics, Inc. is headquartered in Brisbane, California. “
ATRA has been the topic of a number of other reports. Goldman Sachs Group Inc. downgraded shares of Atara Biotherapeutics from a “neutral” rating to a “sell” rating and dropped their target price for the stock from $23.00 to $16.00 in a report on Thursday, September 15th. Jefferies Group reiterated a “buy” rating and issued a $25.00 target price on shares of Atara Biotherapeutics in a report on Sunday, July 10th. Citigroup Inc. boosted their target price on shares of Atara Biotherapeutics from $8.00 to $10.00 and gave the stock a “sell” rating in a report on Friday, August 19th. Finally, JMP Securities reiterated a “buy” rating on shares of Atara Biotherapeutics in a report on Saturday, July 9th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company’s stock. Atara Biotherapeutics currently has an average rating of “Hold” and an average price target of $26.14.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/10/atara-biotherapeutics-inc-atra-upgraded-to-hold-by-zacks-investment-research.html
Shares of Atara Biotherapeutics (NASDAQ:ATRA) traded up 6.81% during trading on Monday, hitting $18.50. 125,724 shares of the company’s stock were exchanged. Atara Biotherapeutics has a 1-year low of $13.31 and a 1-year high of $40.80. The firm’s market capitalization is $533.00 million. The stock’s 50 day moving average is $20.16 and its 200 day moving average is $20.32.
Atara Biotherapeutics (NASDAQ:ATRA) last released its earnings results on Monday, August 8th. The company reported ($0.66) EPS for the quarter, missing analysts’ consensus estimates of ($0.61) by $0.05. On average, equities research analysts forecast that Atara Biotherapeutics will post ($2.85) earnings per share for the current year.
In related news, COO Gad Soffer sold 5,356 shares of the business’s stock in a transaction that occurred on Tuesday, August 16th. The shares were sold at an average price of $22.41, for a total transaction of $120,027.96. Following the transaction, the chief operating officer now directly owns 146,460 shares of the company’s stock, valued at $3,282,168.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Isaac E. Ciechanover sold 9,600 shares of the business’s stock in a transaction that occurred on Thursday, July 21st. The shares were sold at an average price of $22.11, for a total transaction of $212,256.00. Following the transaction, the chief executive officer now directly owns 223,228 shares in the company, valued at $4,935,571.08. The disclosure for this sale can be found here. Corporate insiders own 16.10% of the company’s stock.
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Barclays PLC increased its position in shares of Atara Biotherapeutics by 2,266.0% in the second quarter. Barclays PLC now owns 4,803 shares of the company’s stock worth $108,000 after buying an additional 4,600 shares during the last quarter. BlackRock Inc. increased its position in shares of Atara Biotherapeutics by 464.3% in the second quarter. BlackRock Inc. now owns 6,100 shares of the company’s stock worth $137,000 after buying an additional 5,019 shares during the last quarter. PNC Financial Services Group Inc. increased its position in shares of Atara Biotherapeutics by 6,736.5% in the second quarter. PNC Financial Services Group Inc. now owns 6,563 shares of the company’s stock worth $148,000 after buying an additional 6,467 shares during the last quarter. Franklin Street Advisors Inc. NC bought a new position in shares of Atara Biotherapeutics during the third quarter worth approximately $214,000. Finally, BlackRock Advisors LLC increased its position in shares of Atara Biotherapeutics by 30.2% in the second quarter. BlackRock Advisors LLC now owns 10,186 shares of the company’s stock worth $229,000 after buying an additional 2,361 shares during the last quarter. 75.50% of the stock is currently owned by hedge funds and other institutional investors.
Atara Biotherapeutics Company Profile
Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. Its segment is the business of developing and commercializing therapeutics. It has approximately two groups of product candidates, such as allogeneic or third-party derived antigen-specific T-cells, and molecularly targeted biologics.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.